Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
10 janv. 2025 09h00 HE
|
Stemline Therapeutics, Inc.
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312)...
Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million
04 mai 2020 07h00 HE
|
Stemline Therapeutics, Inc.
Acquisition of Stemline establishes Menarini’s presence in the U.S. biopharmaceutical oncology market Menarini will support further development of Stemline’s ELZONRIS® and enable global expansion by...
Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results
13 mars 2020 16h45 HE
|
Stemline Therapeutics, Inc.
Net revenue for ELZONRIS® was $11.8 million for the fourth quarterConference call and live webcast scheduled for Monday, March 16th, at 8:00 AM ET NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) --...
Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020
11 mars 2020 16h05 HE
|
Stemline Therapeutics, Inc.
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference
26 févr. 2020 07h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers
13 janv. 2020 16h15 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
08 janv. 2020 16h15 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting
10 déc. 2019 08h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer
06 déc. 2019 18h30 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting
06 déc. 2019 07h00 HE
|
Stemline Therapeutics, Inc.
NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...